Pharmaceutical Technology, Apr 1, 2009 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Apr 1, 2009
Articles
Influence of Superdisintegrants on the Rate of Drug Dissolution from Oral Solid Dosage Forms
By Jagdish Balasubramaniam , Tim Bee
The authors examine common superdisintegrants (i.e., crospovidone Type A, crospovidone Type B, croscarmellose sodium, and sodium starch glycolate) with a set of poorly soluble drug actives and evaluate in vitro drug dissolution.
Roller Compaction of Anhydrous Lactose and Blends of Anydrous Lactose with MCC
By Sander van Gessel , Henk van Duinen , Ivan Bogaerts
The authors studied the behavior of anhydrous lactose and the combination of anhydrous lactose and the combination of anhydrous lactose with microcrystalline cellulose on a pilot-scale roller compactor.
Using Polymers to Enhance Solubility of Poorly Soluble Drugs
By Kathrin Nollenberger , Andreas Gryczke , Takayuki Morita , Tatsuya Ishii
The authors demonstrate how melt-extrusion and spray-drying methods can help to prepare solid dispersions of poorly soluble drugs using Eudragit polymers.
A New Hypromellose Excipient for Direct Compression and Controlled Release
By Mark J. Hall , Brian D. Koblinski , Harold W. Bernthal , Karl V. Jacob , Kacee B. Ender
The authors examine the use of a hypromellose-based product as an excipient in a controlled release formulation using direct-compression tableting.
A Novel Pregelatinized Starch as a Sustained-Release Matrix Excipient
By Masaaki Endo , Kazuhiro Obae , Yoshihito Yaginuma
The authors examine the use of a novel highly functional pregelatinized starch as a controlled-release matrix excipient.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here